What is Takeda Pharmaceutical Co. Ltd.?
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally.
TKPHF · Verdict
Moderate reward · moderate risk
TKPHF stands out on volatility and valuation, but watch the balance sheet signal.
Based on 88% data coverage
TKPHF · Verdict
Top decile vs peers
P/E 13.1× · PEG 0.41
15% free-cash-flow margin
Interest covered 2.3×
Rev +8.7% CAGR · earnings -22.3%
Model-based scoring. For information only — not financial advice.
Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma-derived therapies, immunology, oncology, and neuroscience. The company is listed on the PINK in USA, operating in the Healthcare sector, with a market capitalisation of 56.72B, and a P/E ratio of 79.4x.
The scoring profile indicates limited reward potential at this time, with valuation and profitability offering the most support. Risk indicators are moderate, consistent with typical market exposure.
For informational purposes only. Not financial advice.